Navigation Links
Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452
Date:5/26/2009

rmulation of CK-1827452 in patients with ischemic cardiomyopathy and angina. Cytokinetics also plans to present data from this trial at the 2009 Heart Failure Congress of the European Society of Cardiology. Top-line data from this trial were included in a Cytokinetics press release in December 2008. The third Phase 2a clinical trial is designed to evaluate an intravenous formulation of CK-1827452 in patients with stable heart failure undergoing clinically indicated coronary angiography in the cardiac catheterization laboratory. Cytokinetics recently initiated its fourth Phase 2a clinical trial of CK-1827452, an open-label, multi-center, multiple-dose trial designed to evaluate and compare the oral pharmacokinetics of both a modified release and an immediate release formulation of CK-1827452 in patients with stable heart failure.

In addition, Cytokinetics has conducted five Phase 1 clinical trials of CK-1827452 in healthy subjects: a first-time-in-humans study evaluating an intravenous formulation, an oral bioavailability study evaluating both intravenous and oral formulations, and three studies of oral formulations: a drug-drug interaction study, a dose proportionality study and a study evaluating modified-release formulations. Data from each of these trials have been reported previously.

Background on Cardiac Myosin Activators and Cardiac Contractility

Cardiac myosin is the cytoskeletal motor protein in the cardiac muscle cell that is directly responsible for converting chemical energy into the mechanical force resulting in cardiac contraction. Cardiac contractility is driven by the cardiac sarcomere, a highly ordered cytoskeletal structure composed of cardiac myosin, actin and a set of regulatory proteins, and is the fundamental unit of muscle contraction in the heart. The sarcomere represents one of the most thoroughly characterized protein machines in human biology. Current inotropic agents, such as beta-ad
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
2. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
3. Preclinical Data From Amgens Oncology Pipeline to be Presented at AACR
4. Amgen to Present at the Cowen and Company Annual Healthcare Conference
5. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
6. Amgens Fourth Quarter 2008 Adjusted Earnings Per Share Increased 6 Percent to $1.06; Full Year 2008 Adjusted Earnings Per Share Increased 6 Percent to $4.55
7. Amgens Breakaway from Cancer Initiative Expands to Help Cancer Patients Access Broad Spectrum of Cancer Resources and Services
8. Amgen Announces Webcast of 2008 Fourth Quarter and Full Year Financial Results
9. Amgen to Present at the 27th Annual JP Morgan Healthcare Conference
10. Amgen Foundation Announces $2.5 Million Expansion of Amgen Scholars Program to Europe
11. Amgen Positioned to Deliver Attractive Growth Over Next Five Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
(Date:7/24/2014)...  Spherix Incorporated (SPEX) -- an intellectual property development ... property, today announced that the Company will issue a ... on Monday, August 18, 2014 for shareholders. Management has ... Monday, August 18, 2014 to discuss the company,s progress ... Anthony Hayes . Following prepared remarks, ...
(Date:7/23/2014)... NEW YORK , July 24, 2014 /PRNewswire/ ... and Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX ... "IMNP."; "Immune" or "the Company"), announced a collaboration ... bullous pemphigoid last night at an event attended ... other interested parties. Lyfebulb is a health and ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Spherix Schedules Shareholder Update Call 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5
... FOREST, Ill., Oct. 7 Hospira, Inc.,(NYSE: HSP ... today announced that it will host a conference call ... 2008, at 8,a.m. Central time., The company will ... stock market open and the conference call., A ...
... Orthocrat Ltd., announced,today that the George Washington ... planning and digital templating,software solution., Orthopedic ... acetate,overlays to determine the size of prosthetic ... adoption of digital imaging,technologies for x-rays, TraumaCad ...
... CITY, Oct. 7 Great Basin Scientific, Inc., ... diagnostic solutions, today announced it had closed a ... in the,funding for this round., The new ... the spring of,2009 as it completes the design ...
Cached Biology Technology:George Washington University Hospital Purchases Orthocrat's TraumaCad(TM) for Orthopedic Preoperative Planning 2George Washington University Hospital Purchases Orthocrat's TraumaCad(TM) for Orthopedic Preoperative Planning 3Great Basin Scientific, Inc. Closes $3.9 Million in Equity Funding 2
(Date:7/24/2014)... Iyer, O.D., a low vision specialist at The University ... School, has been awarded a grant to help Harris ... eyeglasses, medication or surgery. , Even with corrective lenses, ... best. However, there are a variety of low vision ... help offset their vision loss. , Iyer is using ...
(Date:7/24/2014)... Atlantic Forest is a hotspot of biodiversity and one ... tree-frogs, and toads) in the world. However, current levels ... few years has been an increase in the description ... the advance of molecular techniques and availability of samples ... number of samples for molecular and morphological analysis, researchers ...
(Date:7/24/2014)... A yearlong study funded by the New Jersey ... J. Bloustein School of Planning and Public Policy at ... Sandy-affected towns are skeptical about the likelihood of community-based ... respondents, 45 percent indicated they were "pessimistic" or "very ... Superstorm Sandy would be rebuilt better than they were ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2A tiny new species of frog from Brazil with a heroic name 2Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2
... her research into single-cell organisms that affect oral health, ... molecular genetics at The University of Texas Health Science ... the 2011 American Society for Microbiology (ASM) Founders Distinguished ... made significant contributions to the society. Goldschmidt joined the ...
... The University of Pennsylvania, Dr. Ron Koder, assistant professor of ... of a team that devised a novel method for producing ... neuroglobin. He was recently awarded a three-year $1.3 million ... artificial blood that can be administered to injured troops on ...
... Biomedical Research Institute (Seattle BioMed) and Northwestern University Feinberg ... the effort to wipe out some of the most ... large structural genomics centers, they,ve experimentally determined 500 three-dimensional ... pathogens, which could potentially lead to new drugs, vaccines ...
Cached Biology News:UTHealth professor to receive service award from American Society for Microbiology 2CCNY professor gets grant to develop 'artificial blood' 2Milestone in fight against deadly disease 2Milestone in fight against deadly disease 3
... EVO Clinical is Tecans open platform for ... quality, safety and performance in the clinical ... provided by flexible barcode reading and sample ... that the system complies with the IVD-Directive* ...
... cycler, flexible on your protocols, easy on your ... high sample throughput instrument at a highly affordable ... format: The truly user-friendly fully interchangeable block system ... of seconds without the need of any tools ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
... Tecans GenePaint system, which is based on ... steps required for performing in situ hybridization of ... key step in the study of gene expression, ... cells and tissues and can be used to ...
Biology Products: